Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ads For Aleve, Tylenol Arthritis Lines Launch In Wake Of NSAID Warning 

This article was originally published in The Tan Sheet

Executive Summary

Bayer and McNeil are taking different marketing approaches for their OTC arthritis analgesics in ads aimed at consumers concerned about NSAID safety

You may also be interested in...



Tylenol Ads Spotlight OTC NSAID Class Link To COX-2 Drugs

A current Tylenol ad campaign capitalizes on FDA's requirement that OTC non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen carry class labeling.

Tylenol Ads Spotlight OTC NSAID Class Link To COX-2 Drugs

A current Tylenol ad campaign capitalizes on FDA's requirement that OTC non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen carry class labeling.

Tylenol Ads Spotlight OTC NSAID Class Link To COX-2 Drugs

A current Tylenol ad campaign capitalizes on FDA's requirement that OTC non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen carry class labeling.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel